CBIO · ISSUER CIK 1253689
CRESCENT BIOPHARMA, INC.
Between Aug 1, 2026 and Oct 29, 2026, 7 CRESCENT BIOPHARMA, INC. insiders reported $0.00 of open-market purchases and $286K of sales on SEC Form 4.
↗7 insiders filed
Original Form 4 filings from Aug 1, 2026 to Oct 29, 2026. 7 of 7 sales were reported under a 10b5-1 plan.
$0.00Insider buying
$286KInsider selling
−$286KNet open-market
Sep 18, 2026Latest filing
| Ticker | Insider | Type | Owned | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sep 18, 202616:03 | Sep 16, 2026 | CBIO | See Remarks | S · Sell10b5-1 | $17.90 | −240 | 13,631 | -2% | −$4K | ||
| Sep 18, 202616:03 | Sep 16, 2026 | CBIO | Chief Scientific Officer | S · Sell10b5-1 | $17.90 | −658 | 21,581 | -3% | −$12K | ||
| Sep 18, 202616:02 | Sep 16, 2026 | CBIO | Chief Medical Officer | S · Sell10b5-1 | $17.90 | −623 | 21,446 | -3% | −$11K | ||
| Sep 18, 202616:02 | Sep 16, 2026 | CBIO | Chief Financial Officer | S · Sell10b5-1 | $17.90 | −568 | 19,730 | -3% | −$10K | ||
| Sep 18, 202616:02 | Sep 16, 2026 | CBIO | See Remarks | S · Sell10b5-1 | $17.90 | −620 | 18,710 | -3% | −$11K | ||
| Sep 18, 202616:02 | Sep 18, 2026from Sep 16, 2026 | CBIO | Chief Executive Officer, Director | S · Sell10b5-1 | $16.91 | −9,447 | 271,765 | -3% | −$160K | ||
| Sep 18, 202616:01 | Sep 18, 2026from Sep 16, 2026 | CBIO | President and COO | S · Sell10b5-1 | $16.90 | −4,570 | 134,588 | -3% | −$77K |